CelVivo Secures $50M to Revolutionize 3D Cell Culture Technology

CelVivo, a cutting-edge biotech start-up specializing in 3D cell culture technology that closely mimics in vivo performance, is thrilled to announce a significant funding milestone of 50,000,000. This substantial investment is a clear endorsement of our vision and effort to revolutionize how cells are cultured for both basic and medical research. Since our inception, CelVivo was driven by the need to cultivate cells in conditions that allow them to regain their full physiological attributes—an accomplishment untouched by traditional cell culture methods. Recognizing that conventional equipment was often impractical and disconnected from the dynamic environment of living organisms, our team developed a novel, semi-automatic, and user-friendly system that bridges the gap between laboratory conditions and the natural in vivo state. This infusion of capital will be strategically allocated to further innovate and refine our technology, expand operational capabilities, and accelerate global collaborations. By collaborating with a diverse network of experts across Europe, Asia, Africa, and the USA, CelVivo remains committed to pushing the boundaries of cellular cultivation technology—creating solutions that not only enhance the reliability of basic research but also pave the way for advanced therapeutic applications. As we celebrate this pivotal achievement, we reaffirm our dedication to transforming cell culture from a traditional science into a modern, practical, and highly effective process that could redefine the landscape of biomedical research worldwide. CelVivo welcomes inquiries and collaborative opportunities as we continue our mission to enable a deeper, more accurate exploration of cellular behavior within a true-to-life environment.